


Multipurpose prevention technologies: Strategy recommendations to guide the most promising products from the lab to hands of women



Bethany Young Holt¹, Susanna Moore¹, Anke Hemmerling², Kavita Nanda³, Greg Kopf³, Thesla Palanee-Phillips⁴, Sharon L. Achilles⁵

¹CAMI Health/Initiative for MPTs, ²UC San Francisco, ³FHI360, ⁴Wits Reproductive Health and HIV Institute, University of the Witwatersrand, ⁵University of Pittsburgh/Magee-Womens Research Institute

BACKGROUND

The **Initiative for MPTs** (IMPT) is a global learning network that advances **multipurpose prevention technologies** (MPTs)—combination products designed to simultaneously prevent **HIV, other sexually transmitted infections (STIs), and/or pregnancy**. Recent results from HIV prevention trials of long-acting antiretroviral formulations¹, in parallel with progress in MPT research, are exciting developments. We outline a strategy for bridging funding and development gaps to identify and guide the most promising MPT candidates through the pipeline.

METHODS

The IMPT completed the annual **MPT Product Development Database** update as detailed in Table 1. We then convened a product-neutral group of multidisciplinary experts to outline a standardized process for establishing benchmark criteria to guide advancement of promising MPT candidates, bridging the funding gap between pre-clinical and clinical development.

RESULTS

As of December 2020, **24 MPT candidates are under development with active funding** (Figures 3-4). Delivery types include: intravaginal rings (IVRs, 11), dissolving inserts (3), vaginal and rectal gels (5), vaginal films (2), implants (1), microarray patches (1); and pills (1). To advance the most promising MPT candidates, the expert group recommends 2 action steps (Table 2).

Table 1: MPT Product Development Database Update

Inclusion Criteria	Resources Used for Update
<ul style="list-style-type: none"> • Good manufacturing practice (GMP) manufactured drug or device • Initiation of IND enabling pre-clinical good laboratory practice (GLP) toxicology studies program • In vivo animal model MPT target indication 	<ul style="list-style-type: none"> • Product developer updates • Peer-reviewed literature • Relevant scientific conferences • Publicly available funding data

Table 2: Action Steps for MPT Field

Recommendations
1. Establish product-neutral multidisciplinary authoritative body, which is sustainable and has agency endorsement and commitment
2. Develop objective, product neutral check list of pre-clinical criteria required by the FDA

Figure 3: MPTs by Development Stage





Figure 4: MPTs by Indication



CONCLUSIONS

The IMPT is working to establish a multidisciplinary product-neutral y authoritative body to establish criteria/standards for MPT product development. Clear, standardized benchmark criteria for MPT product evaluation and agency commitment to support panel recommendations will help expedite development of the most promising MPT candidates and stimulate MPT support and innovation.



ACKNOWLEDGMENTS Special thanks to James Kiarie (WHO), Daniel Johnston & Travis Kent (NICHD CRB), Joe Romano (NWJ Group), Nomita Chandhiok (ICMR), and Kathreen Daria (IMPT) for their contributions.

CITATIONS ¹World Health Organization. (2020, November 9). *Trial results reveal that long-acting injectable cabotegravir as PrEP is highly effective in preventing HIV acquisition in women*. World Health Organization. <https://www.who.int/news/item/09-11-2020-trial-results-reveal-that-long-acting-injectable-cabotegravir-as-prep-is-highly-effective-in-preventing-hiv-acquisition-in-women>

This activity is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of Cooperative Agreement #AID-OAA-A-16-00045.

HIV RESEARCH FOR PREVENTION
27 & 28 JAN | 3 & 4 FEB 2021

